Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with clinicians from Scripps Clinic, have identified that the loss of two genes drives the formation of serrated colorectal cancer—yielding potential biomarkers. The research has also identified a combination treatment that has treated the cancer in mice. The study published today in Immunity.
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified gene recombination in neurons that produces thousands of new gene variants within Alzheimer’s disease brains. The study, published today in Nature, reveals for the first time how the Alzheimer’s-linked gene, APP, is recombined by using the same type of enzyme found in HIV.
SBP today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating an inflammation-inhibiting biologic that arose from a research collaboration between Eli Lilly and Company (Lilly) and SBP formed in 2015.
Sepsis remains a common and deadly condition that occurs when the body reacts to an infection in the bloodstream. However, scientists know little about the early stages of the condition. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC Santa Barbara have discovered that host responses during sepsis progression can vary in important ways based on pathogen type—which could lead to more effective treatments. The study published today in Cell Host and Microbe.
For children born with Saul-Wilson syndrome, and their parents, much of their lives are spent searching for answers. First defined in 1990, only 14 cases are known worldwide. Today, these individuals have answers. A study published today in the American Journal of Human Genetics, has uncovered the cause of Saul-Wilson syndrome.
Trustees of Sanford Burnham Prebys Medical Discovery Institute elect new Board leadership, welcome new Board member
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have developed new single-cell approaches wedded to machine learning. This has revealed thousands of previously unknown DNA changes arising during prenatal life in the developing mouse brain. The study published today in PNAS.
Scientists continue to unravel links between body weight and the gut microbiome. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP) report an unexpected finding: mice fed a fatty diet and mannose, a sugar, were protected from weight gain, leaner and more fit—and this effect tracked with changes in the gut microbiome. The study published today in Cell Reports.
Inflammatory bowel disease (IBD), an umbrella term for a number of gut disorders—including ulcerative colitis and Crohn’s disease—remains a clinical challenge. Now, researchers from Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with scientists at Technion – Israel Institute of Technology, have identified a protein that drives intestinal inflammation. This finding highlights new opportunities for creating targeted therapeutics. The study published today in Cell Reports.
Astrocytes' important role in brain function suggests they are also involved in disease. Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified an astrocyte subpopulation as the dominant cell type to spring into action in vivo (in a living organism) in a neuroinflammatory disease setting. The study published today in eNeuro.
Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have found that the anti-malaria drug amodiaquine inhibits the apelin receptor protein, which helps drive the vascularization behind diabetic retinopathy, wet age-related macular degeneration (AMD) and other conditions. Because the drug has been approved to treat malaria for decades, it could move relatively quickly through the pipeline to help patients. The study was published in the journal PLOS ONE.
Using genetic and pharmacological means, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) were surprised to find that blocking LDHA had only a limited impact on melanoma cells, since they were able to redirect energy production. Their results identify an alternative growth pathway driven by a molecule called ATF4, revealing new potential targets for drug development. The study was published today in EMBO Journal.
Ever wonder why you burn fat and heat up when you exercise or shiver? Now, researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) have shown that sarcolipin, a small peptide only found in muscles, increases muscle energy expenditure and fat oxidization. The study was published today in the journal Cell Reports.
Answers to treating muscular dystrophies could lie in better understanding muscle repair—which resembles a delicate cellular dance choreographed by special cells called fibro-adipogenic progenitors (FAPs). Researchers already know these cells have a dark side—they are also responsible for the muscle wasting and scarring that occurs during Duchenne muscular dystrophy (DMD). Now, scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have revealed that FAPs don’t have just one identity—but several distinct identities that emerge during key stages of muscle regeneration. Importantly, the FAPs that drive the symptoms of DMD have defined markers, meaning they could be targeted for drug development. The study was published in Nature Communications.
Breast cancer researcher Svasti Haricharan joins SBP faculty
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively licensed in 2015 to a private company, DrugCendR Inc. The drug candidate was discovered in the laboratory of Erkki Ruoslahti, M.D., Ph.D., distinguished professor at SBP and founder, president and CEO of DrugCendR.
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with the Fondazione Santa Lucia IRCCS in Rome, have discovered a new disease-specific role of FAP cells in muscle wasting and scarring, indicating a potential new avenue for treating motor neuron diseases.
Sanford Burnham Prebys Medical Discovery Institute (SBP) announced today that Louie Coffman has been appointed chief administrative officer and chief financial officer, and Angelica Gamble-Wong has been appointed vice president of Human Resources (HR).
SBP is pleased to announce that it has been awarded four Padres Pedal the Cause (PPTC) collaborative grants with UCSD Moores Cancer Center. The projects funded include research to help understand cancer and find novel therapies that exploit its vulnerabilities. The awards are part of the $2.4 million raised in the November 2017 cycling event—the largest annual contribution in the five-year history of the organization.
Sanford Burnham Prebys is one of 70 National Cancer Institute (NCI)-designated cancer centers to issue a statement urging for increased HPV vaccination and screening to eliminate HPV-related cancers, starting with cervical cancer. These institutions collectively recognize insufficient vaccination as a public health threat and call upon the nations’ physicians, parents and young adults to take advantage of this rare opportunity to eliminate several different types of cancer in men and women.
A new study by Sanford Burnham Prebys (SBP) researchers describes how a specific nuclear pore component is critical for the survival of circulating T cells. The findings, published in Nature Immunology, identify a new node of T cell receptor signaling and could pave the way for the development of future immunotherapies.
SBP researchers recently discovered an alternative metabolic pathway that might be used by cancer cells to survive nutrient deprivation. Targeting these proteins to disrupt autophagy in cancer cells is an exciting therapeutic strategy that could minimize toxicity.
A new study by Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers helps explain the connection between a tumor suppressor called protein kinase C zeta (PKC zeta) and metastatic colorectal cancer.
A coalition of brain scientists and civic leaders, including Mayor Kevin Faulconer and county Supervisors Dianne Jacob and Kristin Gaspar, announced that the federal government has awarded a $1.3 million grant to Sanford Burnham Prebys Medical Discovery Institute to advance the local search for a cure for Alzheimer's.
Sanford Prebys Medical Discovery Institute (SBP) researchers recently discovered that that inactivation of a protein called p62 in fat cells fuels aggressive, metastatic prostate cancer in mice. The findings suggest that mTOR inhibitors currently used to treat a wide range of cancers may have the unintended consequence of shutting down fat tissue metabolism and fueling tumor growth.
Evan Y. Snyder, M.D., Ph.D., professor and founding director, Center for Stem Cells & Regenerative Medicine at Sanford Burnham Prebys Medical Discovery Institute (SBP) and professor at the University of California San Diego, has been elected to membership in the Association of American Physicians (AAP).
SBP researchers have revealed how TREM2, a receptor found on immune cells in the brain, interacts with toxic amyloid beta proteins to restore neurological function. The research suggests boosting TREM2 levels in the brain may prevent or reduce the severity of neurodegenerative disorders including Alzheimer’s disease.
SBP researchers have discovered that accumulation of ceramides—a type of lipid (fat)— plays a crucial role in lipotoxic cardiomyopathy (LCM)—a heart condition that often occurs in patients with diabetes and obesity. The study, published today in Cell Reports, also identified several potential therapeutic targets that could prevent or reverse the effects of LCM.
SBP researchers have developed the first ever high-throughput, genome-scale imaging-based approach to investigate protein stability. The method has been used to identify several previously unknown human proteins that HIV degrades to enhance its infection process.
New research from Sanford Burnham Prebys Medical Discovery Institute (SBP) reveals a novel gene regulatory system that may advance stem cell therapies and gene-targeting treatments for neurological diseases such as Alzheimer’s disease, Parkinson’s disease, and mental health disorders that affect cognitive abilities.
Small bacterial infections that may go unnoticed and which the body easily clears without treatment, such as occurs during mild food poisoning, nevertheless can start a chain of events that leads to chronic inflammation and potentially life-threatening colitis.
A new study led by SBP describes the biology behind why muscle stem cells respond differently to aging or injury. The findings, published in Cell Stem Cell, have important implications for the normal wear and tear of aging.
SBP and Technion Institute researchers have SHARPIN-ed their knowledge of how a malicious form of a protein drives the formation of melanoma through modulation of the PRMT5 pathway. The new research was published in The Journal of Clinical Investigation.
Scientists have identified a mechanism that explains the development of hyperaldosteronism, a condition in which the adrenal glands produce too much aldosterone, The findings, published in JCI Insight, offer a path for drug discovery to treat the condition.
Maximiliano D’Angelo, Ph.D., an assistant professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), has received a four-year, $792,000 Research Scholar Grant from the American Cancer Society.
Florida researchers have identified a signaling pathway that is essential for angiogenesis, the growth of new blood vessels from pre-existing vessels. The findings, published in Nature Communications, may improve current strategies to improve blood flow in ischemic tissue, such as that found in atherosclerosis and peripheral vascular disease associated with diabetes.
Researchers have demonstrated that the drug palovarotene suppresses the formation of bony tumors (osteochondromas) in models of multiple hereditary exostoses (MHE). The research, published in the Journal of Bone and Mineral Research, is an important step toward an effective pharmacological treatment for MHE, a rare genetic condition that affects about 1 in 50,000 people worldwide.
California researchers have discovered that a medication used to prevent and treat malaria may also be effective for Zika virus. The drug, called chloroquine, has a long history of safe use during pregnancy, and is relatively inexpensive. The research was published today in Scientific Reports.
Scientists have shown that a protein called membralin is critical for keeping Alzheimer’s disease pathology in check. The study, published in Nature Communications, shows that membralin regulates the cell’s machinery for producing beta-amyloid (or amyloid beta, Aβ), the protein that causes neurons to die in Alzheimer’s disease.
Researchers at SBP have identified a peptide that could lead to the early detection of Alzheimer’s disease (AD). The discovery, published in Nature Communications, may also provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson’s disease, as well as glioblastoma, brain injuries and stroke.
Researchers have identified a new protective function for a brain protein genetically linked to Alzheimer’s. The findings, published in the Journal of Experimental Medicine, could inform novel treatment strategies to combat neurodegenerative diseases.
A new study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies potential new therapeutic avenues for patients with Alagille syndrome.
Jamey Marth, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute (SBP), is the 2017 recipient of the Society for Glycobiology’s Karl Meyer Award. The international award is given to well-established scientists with currently active research programs who have made widely recognized major contributions to the field of glycobiology. Marth is also the Carbon Professor of Biochemistry and Molecular Biology, Mellichamp Professor of Systems Biology, and Director of the Center for Nanomedicine at UC Santa Barbara.
Stromal tissue may provide novel targets to disrupt tumor supply lines
Sanford Burnham Prebys Medical Discovery Institute Announces Two New Members to the Board of Trustees
New class of drug may help treat cocaine and nicotine addiction
Assistant professor aims to identify drugs that deplete tumors of nutrition.
By fleshing out how one signaling receptor contributes to causing obesity through its activity in fatty tissue but not in muscle cells, SBP scientists have zeroed in on an important new avenue of exploration for combating metabolic disease. More than one-third of American adults are considered to be obese, which dramatically increases their risk for developing type 2 diabetes, non-alcoholic fatty liver disease, high blood pressure, and multiple inflammatory conditions.
SBP researchers advance tumor-imaging nanosystem for enhanced diagnostic imaging
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right